Cargando…

The role of DLL1 in long-term vascular normalization and cancer immunotherapy

Detalles Bibliográficos
Autores principales:	Wu, Qiaozhen, Huang, Yuhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610167/ https://www.ncbi.nlm.nih.gov/pubmed/34708998 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0507

Ejemplares similares

Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine
por: Shimizu, Hiromichi, et al.
Publicado: (2014)

Normal Development in Mice Over-Expressing the Intracellular Domain of DLL1 Argues against Reverse Signaling by DLL1 In Vivo
por: Redeker, Christian, et al.
Publicado: (2013)

The Role of Dll4/Notch Signaling in Normal and Pathological Ocular Angiogenesis: Dll4 Controls Blood Vessel Sprouting and Vessel Remodeling in Normal and Pathological Conditions
por: Lobov, Ivan, et al.
Publicado: (2018)

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
por: Geffers, Insa, et al.
Publicado: (2007)

Context-Dependent Functional Divergence of the Notch Ligands DLL1 and DLL4 In Vivo
por: Preuße, Kristina, et al.
Publicado: (2015)

The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro
por: Tveriakhina, Lena, et al.
Publicado: (2018)

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy
por: Fan, Peng, et al.
Publicado: (2022)

The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development
por: Fasoulakis, Zacharias, et al.
Publicado: (2022)

The Role of Cytoskeleton Protein 4.1 in Immunotherapy
por: Si, Chaohua, et al.
Publicado: (2023)

Clinical implications of DLL4 expression in gastric cancer
por: Ishigami, Sumiya, et al.
Publicado: (2013)

DLL3 Is a Prognostic and Potentially Predictive Biomarker for Immunotherapy Linked to PD/PD-L Axis and NOTCH1 in Pancreatic Cancer
por: Lacalle-Gonzalez, Carlos, et al.
Publicado: (2023)

Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo
por: Trindade, Alexandre, et al.
Publicado: (2017)

DLL3: an emerging target in small cell lung cancer
por: Owen, Dwight H., et al.
Publicado: (2019)

Therapeutic promise and challenges of targeting DLL4/NOTCH1
por: Yan, Minhong
Publicado: (2011)

Maintenance of Bone Homeostasis by DLL1‐Mediated Notch Signaling
por: Muguruma, Yukari, et al.
Publicado: (2017)

Dll1 haploinsufficiency causes brain abnormalities with functional relevance
por: Arzate, Dulce-María, et al.
Publicado: (2022)

Emerging Roles of Chemokines in Cancer Immunotherapy
por: Moser, Bernhard
Publicado: (2022)

Dll4 blockade interferes with the bone marrow vascular niche and perturbs hematopoietic recovery following myeloablation
por: Remédio, Leonor, et al.
Publicado: (2010)

Dll1 Marks Cells of Origin of Ras-Induced Cancer in Mouse Squamous Epithelia
por: Vasilaki, Eleni, et al.
Publicado: (2018)

The Notch ligand DLL1 exerts carcinogenic features in human breast cancer cells
por: Sales-Dias, Joana, et al.
Publicado: (2019)

Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer
por: Kumar, Sushil, et al.
Publicado: (2018)

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
por: Cali Daylan, Ayse Ece, et al.
Publicado: (2023)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

The Regulation of para-Nitrophenol Degradation in Pseudomonas putida DLL-E4
por: Chen, Qiongzhen, et al.
Publicado: (2016)

Anti-DLL4, a cancer therapeutic with multiple mechanisms of action
por: Gurney, Austin, et al.
Publicado: (2011)

DLL3 regulates Notch signaling in small cell lung cancer
por: Kim, Jun W., et al.
Publicado: (2022)

Special Issue: The Role of Complement in Cancer Immunotherapy
por: Taylor, Ronald P.
Publicado: (2021)

Unraveling immunotherapy's role in propelling cancer outcomes
por: Ji, Ning, et al.
Publicado: (2023)

Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling
por: Watson, Oliver, et al.
Publicado: (2013)

Vascular normalization and immunotherapy: Spawning a virtuous cycle
por: Swamy, Kumara
Publicado: (2022)

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms
por: Yao, James, et al.
Publicado: (2022)

Motor neuron-derived Thsd7a is essential for zebrafish vascular development via the Notch-dll4 signaling pathway
por: Liu, Lawrence Yu-Min, et al.
Publicado: (2016)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer
por: Isobe, Yoshitaka, et al.
Publicado: (2020)

Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development
por: You, Weon-Kyoo, et al.
Publicado: (2023)

Expressions and Prognostic Values of Notch3 and DLL4 in Human Breast Cancer
por: Wang, Lin, et al.
Publicado: (2023)

Spatiotemporal oscillations of Notch1, Dll1 and NICD are coordinated across the mouse PSM
por: Bone, Robert A., et al.
Publicado: (2014)

The potential value of Notch1 and DLL1 in the diagnosis and prognosis of patients with active TB
por: Xie, Jinling, et al.
Publicado: (2023)

Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia
por: Xiong, Huizhong, et al.
Publicado: (2021)

PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors
por: Iwamoto, Hideki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ml30l7ilaaj2ks3ugqnrnss5p1